These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30834056)

  • 1. Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.
    De Vecchis R; Soreca S; Ariano C
    Cardiol Res; 2019 Feb; 10(1):24-33. PubMed ID: 30834056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
    De Vecchis R; Ariano C; Soreca S
    Minerva Cardioangiol; 2019 Jun; 67(3):214-222. PubMed ID: 30895762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Raja R; Kumari S; Umer Khan M; Ayaz A; Jaffar D; Mohamad Z; Muzammil MA; Sohail N; Ahmed Qureshi S; Saeed H; Fahad Amin M; Jawad A; Varrassi G; Kumar S; Khatri M; Maryam A
    Cureus; 2023 Nov; 15(11):e48692. PubMed ID: 38090459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.
    Zhang Y; Zhao X; Huang H; Li M
    Clin Res Cardiol; 2023 Jul; 112(7):855-867. PubMed ID: 36326841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.
    Almarjan AI; Almarjan SA; Masoud AT
    High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
    Wu HX; Liu KK; Li BN; Liu S; Jin JC
    Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Chua SK; Lai WT; Chen LC; Hung HF
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34206864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Sacubitril/Valsartan in Hypertension.
    Malik AH; Aronow WS
    Am J Ther; 2022 May-Jun 01; 29(3):e322-e333. PubMed ID: 30664018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
    Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J
    Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
    Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
    Yang S; Zhang H; Yang P; Wang C; Wu Q
    J Cardiovasc Pharmacol; 2021 May; 77(5):650-659. PubMed ID: 33951700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension.
    Zheng L; Xia B; Zhang X; Zhao Y
    Cardiol Res Pract; 2021; 2021():8867578. PubMed ID: 33824765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
    Xiong B; Nie D; Qian J; Yao Y; Yang G; Rong S; Zhu Q; Du Y; Jiang Y; Huang J
    ESC Heart Fail; 2021 Dec; 8(6):4852-4862. PubMed ID: 34716749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
    Gao J; Zhang X; Xu M; Deng S; Chen X
    Front Pharmacol; 2023; 14():1237210. PubMed ID: 37601056
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    Huang Y; Zhang Y; Ma L; Zhou H; Fang C; Chen C
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):202-210. PubMed ID: 33929386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.